Polycythemia vera a rare type of blood cancer that begins in the bone marrow. Polycythemia vera is considered when the hematocrit reaches more than 48% in women and 52% in men while haemoglobin level of greater than 16.5g/Dl in women and 18.5g/Dl in men.
In polycythemia vera, the bone marrow produces too many red blood cells which can lead to blood clots due to thickening of the blood. Polycythemia vera consists of following symptoms such as headache, weakness, shortness of breathing, dizziness, double vision and sweating usually during the night.
Polycythemia vera gets worse with time if remain undiagnosed can be life-threatening. Polycythemia vera can be treatable but cannot be curable. Polycythemia vera treatment may include phlebotomy and drug therapy.
Phlebotomy involves the removal of blood from the body. Drug therapy involves the use of Hydroxyurea and Interferon-alfa.Patients who do not respond to hydroxyurea are treated with ruxolitinib(jakafi) or busulfan.
Global polycythemia treatment market is increasing rapidly due to the rising number of cases.
Sometimes a low dose of aspirin, allopurinol and antihistamines are also preferred for polycythemia vera treatment. Givinostat is an emerging drug in polycythemia vera treatment market.
It is an orally bioavailable hydroxyl inhibitor of histone deacetylase with potential anti-angiogenic, antineoplastic and anti-inflammatory activities.Another drug PTG-300 is under trial phase. It mimics the properties of the natural hormone hepicidin.
Increasing prevalence of the cases is expected to drive the growth of the polycyhthemia vera treatment market. Rising awareness among the people about the disease and a better understanding of the disease by biotechnology industries is expected to drive the growth of the polycythemia vera treatment market.
Growing environmental stress due to which exposure to toxic substances is increasing is expected to drive the growth of polycythemia vera treatment market, as it may cause mutation in the cells which is one of the main cause of polycythemia vera disease.
Researchers are focusing on developing new therapies for treating polycythemia vera, which in turn is expected to drive the growth of polycythemia vera treatment market.Polycythemia vera treatment market has been segmented on the basis of drug class, route of administration and distribution channel
The global polycythemia vera treatment market is expected to be dominated by antimetabolite drug due to its success rate on treating the disease as compared to other drugs in the market.
It has become a drug of choice and is expected to experience steady growth over the forecast period. Based on the route of administration, the oral route is the most frequently used route of administration.
Based on the distribution channel, hospital pharmacies are expected to be the most profitable segment in polycythemia vera treatment market.
North America is expected to have the major share of the polycythemia vera treatment market due to higher prevalence of the disease. North America followed by Europe is expected to be the second most profitable region in the global polycythemia vera treatment market.
Asia-Pacific is expected to be the fastest-growing polycythemia vera treatment market due to rising population in countries like India and China. Latin America market is expected to experience a constant growth whereas the Middle east and Africa is expected to be the least profitable market due to lower adoption of drugs.
The key participants operating in the global polycythemia vera treatment market are:
- Pfizer Inc
- Galena Biopharma
- Bristol-Myers Squibb Company
- Novartis AG
- Eli Lilly and Company
- PharmaEssentia Corporation
- Bayer AG
- Mylan N.V.
- Teva Pharmaceuticals Industries Ltd
- GlaxosmithKline plc
The report covers exhaustive analysis on:
- Polycythemia Vera Treatment market Segments
- Polycythemia Vera Treatment Market Dynamics
- Historical Actual Market Size, 2015 - 2019
- Polycythemia Vera Treatment market Size & Forecast 2020 to 2030
- Polycythemia Vera Treatment Market Current Trends/Issues/Challenges
- Competition & Companies involved
- Polycythemia Vera Treatment Market Drivers and Restraints
Regional analysis includes
- North America
- Latin America
- Asia Pacific
- Middle East & Africa
Impact of COVID-19 on Polycythemia Vera Treatment Market:
During this COVID-19 pandemic, pharmaceutical companies, medical devices companies and also biotechnology companies are facing rapid challenges that are arising from the disruption in supply chains and the need to change business processes.
As the studies showed, that there is no correlation between blood cancer and coronavirus, polycythemia vera treatment market is being affected by this pandemic. If COVID-19 pandemic continues for a medium/long period, it may impact the supply of active material and ingredients globally as well as the import and export of drugs.
There has been a disruption in the treatment market. As coronavirus has become the main focus, all research institutes, biotech and pharmaceutical companies are appointed in collaboration work to deal with Covid-19.
- Shifting Industry dynamics
- In-depth market segmentation
- Historical, current and projected industry size recent industry trends
- Key Competition landscape
- Strategies for key players and product offerings
- Potential and niche segments/regions exhibiting promising growth
- A neutral perspective towards market performance
By drug class:
- Kinase Inhibitors
- Alpha Interferon
- Selective Serotonin Reuptake Inhibitors
By route of administration:
By distribution channel:
- Hospital Pharmacies
- Retail Pharmacies
- Drug store
- Online sales
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.